Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use
Harry E. Prince, Tara S. Givens, Mary Lapé-Nixon, Nigel J. Clarke, Dale A. Schwab, Hollis J. Batterman, Robert S. Jones, William A. Meyer, Hema Kapoor, Charles M. Rowland, Farnoosh Haji‐Sheikhi, Elizabeth M. Marlowe
Abstract
= 584) ranged from 94.3% to 100%. Laboratory-developed inhibition assays were utilized to evaluate 49 consensus-negative samples that were positive in only one assay; true-positive reactivity was confirmed in only 2 of these 49 (4%) samples. These findings demonstrate very high levels of agreement among 4 SARS-CoV-2 IgG assays authorized for emergency use, regardless of antigen target or assay format. Although false-positive reactivity was identified, its occurrence was rare (no more than 1.7% of samples for a given assay).
Topics & Concepts
Spike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunoassayCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakAntibodyImmunoglobulin GMedicineCoronavirusImmunologyOutbreakInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingAdvanced biosensing and bioanalysis techniques